Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.

doi:10.1200/JCO.21.02143

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Feb 2022

Shouval Roni, Alarcon Tomas Ana, Fein Joshua A, Flynn Jessica R, Markovits Ettai, Mayer Shimrit, Olaide Afuye Aishat, Alperovich Anna, Anagnostou Theodora, Besser Michal J, Batlevi Connie Lee, Dahi Parastoo B, Devlin Sean M, Fingrut Warren B, Giralt Sergio A, Lin Richard J, Markel Gal, Salles Gilles, Sauter Craig S, Scordo Michael, Shah Gunjan L, Shah Nishi, Scherz-Shouval Ruth, van den Brink Marcel, Perales Miguel-Angel, Palomba Maria Lia

Abstract excerpt

PURPOSE: Tumor-intrinsic features may render large B-cell lymphoma (LBCL) insensitive to CD19-directed chimeric antigen receptor T cells (CAR-T). We hypothesized that TP53 genomic alterations are detrimental to response outcomes in LBCL treated with CD19-CAR-T. MATERIALS AND METHODS: Patients with LBCL treated with CD19-CAR-T were included. Targeted next-generation sequencing was performed on pre-CAR-T tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biological Products

Share to DNA Copy Number Variations

Share to Gene Dosage

Share to Immunotherapy, Adoptive

Share to Lymphoma, B-Cell

Share to Receptors, Antigen, T-Cell

Share to Receptors, Chimeric Antigen

Source

Open in PubMed Open full text

Identifiers

PMID: 34860572
DOI: 10.1200/JCO.21.02143
PMCID: PMC8797602

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.PMID 34860572Read ↗

Impact of TP53 mutations on survival outcomes in the CAR-T era of large B-cell lymphoma.Semantic proximity Read ↗

Genomic drivers of large B-cell lymphoma resistance to CD19 CAR-T therapySemantic proximity Read ↗

Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial.Semantic proximity Read ↗

Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphomaSemantic proximity Read ↗

TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era.Semantic proximity Read ↗

Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST studySemantic proximity Read ↗

Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.Semantic proximity Read ↗

TP53 mutation and survival in aggressive B cell lymphoma.Semantic proximity Read ↗

Clonal hematopoiesis is associated with increased toxicity in large B-cell lymphoma patients treated with chimeric antigen receptor T cell therapySemantic proximity Read ↗

Real-world routine diagnostic molecular analysis for TP53 mutational status is recommended over p53 immunohistochemistry in B-cell lymphomas.Semantic proximity Read ↗

CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.